Samalizumab

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]

Samalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD200
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6542H10086N1702O2102S46
Molar mass147687.22 g·mol−1
 NY (what is this?)  (verify)

Samalizumab was developed by Alexion Pharmaceuticals.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.